A Phase 1 interventional study of BI 894416 and Placebo in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-18.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This first-in man trial is designed to investigate the safety and tolerability of BI 894416 in healthy male subjects following oral administration of single rising doses.
Pharmacokinetics (PK) including dose proportionality after single dosing of BI 894416 as oral solution will be explored, the investigation of PK of BI 894416 as tablet formulation and the exploration of relative bioavailability of BI 894416 as tablet formulation compared to oral solution.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
In addition, the following trial-specific exclusion criteria apply:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single Rising Dose (SRD) Part
Drug: Placebo
SRD Part
Drug: BI 894416
SRD Part
Drug: BI 894416
SRD Part
Drug: BI 894416
SRD Part
Drug: BI 894416
SRD Part
Drug: BI 894416
SRD Part
Drug: BI 894416
SRD Part
Drug: BI 894416
BI 894416 10 mg tablet (tb) / BI 894416 10 mg powder for oral solution (PfOS) / BI 894416 4\*10 mg tablets. Relative bioavailability (rel BA) part
Drug: BI 894416
BI 894416 10 mg powder for oral solution (PfOS) / BI 894416 10 mg tablet (tb) / BI 894416 4\*10 mg tablets. Relative bioavailability (rel BA) part.
Drug: BI 894416
Percentage of Participants With Drug-related Adverse Events in SRD Part
Percentage of participants with drug-related adverse events (AEs) in SRD part. Percentages are calculated using total number of subjects per treatment as the denominator. Percentages were rounded up to 1 decimal places.
Time frame: From drug administration until end of the trial, up to 17 days.
Area Under the Concentration-time Curve of BI 894416 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-inf) in SRD Part
Area under the concentration-time curve of BI 894416 in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf) in SRD part is presented.
Time frame: Pharmacokinetic samples were collected at 2 hours (h) prior drug administration and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 34, 48, 72, 96, 168 h after drug administration.
Maximum Measured Concentration of BI 894416 in Plasma (Cmax) in SRD Part
Maximum measured concentration of BI 894416 in plasma (Cmax) in SRD part is presented.
Time frame: Pharmacokinetic samples were collected at 2 hours (h) prior drug administration and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 34, 48, 72, 96, 168 h after drug administration.
Area Under the Concentration-time Curve of BI 894416 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) in Rel BA Part
Area under the concentration-time curve of BI 894416 in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) in rel BA part is presented. "BI 894416 40 mg tb" arm was compared in a descriptive fashion with other dose groups without statistical analysis.
Time frame: Pharmacokinetic samples were collected at 2 hours (h) prior drug administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 h after drug administration.
Area Under the Concentration-time Curve of BI 894416 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-inf) in Rel BA Part
Area under the concentration-time curve of BI 894416 in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf) in rel BA part is presented. "BI 894416 40 mg tb" arm was compared in a descriptive fashion with other dose groups without statistical analysis.
Time frame: Pharmacokinetic samples were collected at 2 hours (h) prior drug administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 h after drug administration.
Maximum Measured Concentration of BI 894416 in Plasma (Cmax) in Rel BA Part
Maximum measured concentration of BI 894416 in plasma (Cmax) in rel BA part is presented. "BI 894416 40 mg tb" arm was compared in a descriptive fashion with other dose groups without statistical analysis.
Time frame: Pharmacokinetic samples were collected at 2 hours (h) prior drug administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 h after drug administration.
Single rising dose (SRD) part was designed as single-blind, partially randomized within dose groups, placebo-controlled, parallel-group design and relative bioavailability (rel BA) part was an open-label, randomized two-way crossover followed by a fixed sequence design in healthy volunteers.
| Milestone | Placebo Matching BI 894416 (SRD Part) | BI 894416 3 Milligram (mg) (SRD Part) | BI 894416 10 mg (SRD Part) | BI 894416 20 mg (SRD Part) | BI 894416 30 mg (SRD Part) | BI 894416 40 mg (SRD Part) | BI 894416 54 mg (SRD Part) | BI 894416 70 mg (SRD Part) | BI 894416 10mg tb / 10mg PfOS / 40mg tb | BI 894416 10mg PfOS / 10mg tb / 40mg tb |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 14 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Completed | 14 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo Matching BI 894416 (SRD Part) | BI 894416 3 Milligram (mg) (SRD Part) | BI 894416 10 mg (SRD Part) | BI 894416 20 mg (SRD Part) | BI 894416 30 mg (SRD Part) | BI 894416 40 mg (SRD Part) | BI 894416 54 mg (SRD Part) | BI 894416 70 mg (SRD Part) | BI 894416 10mg tb / 10mg PfOS / 40mg tb | BI 894416 10mg PfOS / 10mg tb / 40mg tb |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 6 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo Matching BI 894416 (SRD Part) | BI 894416 3 Milligram (mg) (SRD Part) | BI 894416 10 mg (SRD Part) | BI 894416 20 mg (SRD Part) | BI 894416 30 mg (SRD Part) | BI 894416 40 mg (SRD Part) | BI 894416 54 mg (SRD Part) | BI 894416 70 mg (SRD Part) | BI 894416 10mg tb / 10mg PfOS / 40mg tb | BI 894416 10mg PfOS / 10mg tb / 40mg tb |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 6 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Percentage of participants with drug-related adverse events (AEs) in SRD part. Percentages are calculated using total number of subjects per treatment as the denominator. Percentages were rounded up to 1 decimal places.
| Percentage of participants | Placebo Matching BI 894416 (SRD Part) | BI 894416 3 Milligram (mg) (SRD Part) | BI 894416 10 mg (SRD Part) | BI 894416 20 mg (SRD Part) | BI 894416 30 mg (SRD Part) | BI 894416 40 mg (SRD Part) | BI 894416 54 mg (SRD Part) | BI 894416 70 mg (SRD Part) |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Drug-related Adverse Events in SRD Part | 0.0 | 0.0 | 0.0 | 33.3 | 16.7 | 0.0 | 16.7 | 16.7 |
Area under the concentration-time curve of BI 894416 in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf) in SRD part is presented.
| nanomole (nmol) * hour (h) / Litre (L) | BI 894416 3 Milligram (mg) (SRD Part) | BI 894416 10 mg (SRD Part) | BI 894416 20 mg (SRD Part) | BI 894416 30 mg (SRD Part) | BI 894416 40 mg (SRD Part) | BI 894416 54 mg (SRD Part) | BI 894416 70 mg (SRD Part) |
|---|---|---|---|---|---|---|---|
| Area Under the Concentration-time Curve of BI 894416 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-inf) in SRD Part | 345 ± 34.9 | 640 ± 101.0 | 1470 ± 96.7 | 3270 ± 27.1 | 6020 ± 20.6 | 7210 ± 28.1 | 11400 ± 29.6 |
Maximum measured concentration of BI 894416 in plasma (Cmax) in SRD part is presented.
| nanomole (nmol)/Litre (L) | BI 894416 3 Milligram (mg) (SRD Part) | BI 894416 10 mg (SRD Part) | BI 894416 20 mg (SRD Part) | BI 894416 30 mg (SRD Part) | BI 894416 40 mg (SRD Part) | BI 894416 54 mg (SRD Part) | BI 894416 70 mg (SRD Part) |
|---|---|---|---|---|---|---|---|
| Maximum Measured Concentration of BI 894416 in Plasma (Cmax) in SRD Part | 55.4 ± 11.1 | 161.0 ± 37.5 | 352.0 ± 26.9 | 527.0 ± 31.3 | 1170.0 ± 26.4 | 1240.0 ± 23.0 | 2130.0 ± 16.7 |
Area under the concentration-time curve of BI 894416 in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) in rel BA part is presented. "BI 894416 40 mg tb" arm was compared in a descriptive fashion with other dose groups without statistical analysis.
| nanomole (nmol) * hour (h)/Litre (L) | BI 894416 10 mg tb (T) | BI 894416 10 mg PfOS (R) | BI 894416 40 mg tb |
|---|---|---|---|
| Area Under the Concentration-time Curve of BI 894416 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) in Rel BA Part | 941 ± 95.2 | 853 ± 89.0 | 5870 ± 61.2 |
Area under the concentration-time curve of BI 894416 in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf) in rel BA part is presented. "BI 894416 40 mg tb" arm was compared in a descriptive fashion with other dose groups without statistical analysis.
| nanomole (nmol) * hour (h)/Litre (L) | BI 894416 10 mg tb (T) | BI 894416 10 mg PfOS (R) | BI 894416 40 mg tb |
|---|---|---|---|
| Area Under the Concentration-time Curve of BI 894416 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-inf) in Rel BA Part | 975 ± 97.5 | 879 ± 90.4 | 6060 ± 63.5 |
Maximum measured concentration of BI 894416 in plasma (Cmax) in rel BA part is presented. "BI 894416 40 mg tb" arm was compared in a descriptive fashion with other dose groups without statistical analysis.
| nanomole (nmol)/Litre (L) | BI 894416 10 mg tb (T) | BI 894416 10 mg PfOS (R) | BI 894416 40 mg tb |
|---|---|---|---|
| Maximum Measured Concentration of BI 894416 in Plasma (Cmax) in Rel BA Part | 199 ± 39.5 | 180 ± 53.4 | 1160 ± 39.2 |
Collected over For SRD part: From drug administration until end of the trial, up to 17 days. For rel BA part: From drug administration until end of the trial, up to 54 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Matching BI 894416 (SRD Part) | 0/14 (0%) | 0/14 (0%) | 3/14 (21.4%) |
| BI 894416 3 Milligram (mg) (SRD Part) | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| BI 894416 10 mg (SRD Part) | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| BI 894416 20 mg (SRD Part) | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| BI 894416 30 mg (SRD Part) | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| BI 894416 40 mg (SRD Part) | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| BI 894416 54 mg (SRD Part) | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| BI 894416 70 mg (SRD Part) | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| BI 894416 10 mg PfOS (R) | 0/12 (0%) | 0/12 (0%) | 4/12 (33.3%) |
| BI 894416 10 mg tb (T) | 0/12 (0%) | 0/12 (0%) | 3/12 (25%) |
| BI 894416 40 mg tb | 0/12 (0%) | 0/12 (0%) | 4/12 (33.3%) |
| Event | Placebo Matching BI 894416 (SRD Part) | BI 894416 3 Milligram (mg) (SRD Part) | BI 894416 10 mg (SRD Part) | BI 894416 20 mg (SRD Part) | BI 894416 30 mg (SRD Part) | BI 894416 40 mg (SRD Part) | BI 894416 54 mg (SRD Part) | BI 894416 70 mg (SRD Part) | BI 894416 10 mg PfOS (R) | BI 894416 10 mg tb (T) | BI 894416 40 mg tb |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/14 | 0/6 | 0/6 | 2/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/12 | 0/12 | 0/12 |
| HeadacheNervous system disorders | 2/14 | 2/6 | 1/6 | 2/6 | 0/6 | 1/6 | 1/6 | 2/6 | 2/12 | 1/12 | 0/12 |
| Abdominal painGastrointestinal disorders | 0/14 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/12 | 0/12 | 0/12 |
| Salivary hypersecretionGastrointestinal disorders | 0/14 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/12 | 0/12 | 0/12 |
| ConjunctivitisInfections and infestations | 0/14 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/12 | 0/12 | 0/12 |
| NasopharyngitisInfections and infestations | 0/14 | 0/6 | 1/6 | 1/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/12 | 0/12 | 0/12 |
| Respiratory tract infectionInfections and infestations | 0/14 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/12 | 0/12 | 0/12 |
| RhinitisInfections and infestations | 0/14 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/12 | 0/12 | 0/12 |
| Arthropod stingInjury, poisoning and procedural complications | 0/14 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/12 | 0/12 | 0/12 |
| Back painMusculoskeletal and connective tissue disorders | 0/14 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/12 | 0/12 | 0/12 |
Treated set (TS): This subject set included all subjects who received at least 1 dose of BI 894416 or placebo.
| Age, Continuous(Years) | Placebo Matching BI 894416 (SRD Part) | BI 894416 3 Milligram (mg) (SRD Part) | BI 894416 10 mg (SRD Part) | BI 894416 20 mg (SRD Part) | BI 894416 30 mg (SRD Part) | BI 894416 40 mg (SRD Part) | BI 894416 54 mg (SRD Part) | BI 894416 70 mg (SRD Part) | BI 894416 10mg tb / 10mg PfOS / 40mg tb | BI 894416 10mg PfOS / 10mg tb / 40mg tb | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 33.8 ± 7.3 | 33.2 ± 7.3 | 33.5 ± 6.4 | 35.7 ± 7.1 | 33.7 ± 7.0 | 38.2 ± 6.3 | 34.3 ± 5.5 | 34.2 ± 9.1 | 31.7 ± 8.3 | 30.5 ± 6.9 | 33.9 ± 7.0 |
| Sex: Female, Male(Participants) | Placebo Matching BI 894416 (SRD Part) | BI 894416 3 Milligram (mg) (SRD Part) | BI 894416 10 mg (SRD Part) | BI 894416 20 mg (SRD Part) | BI 894416 30 mg (SRD Part) | BI 894416 40 mg (SRD Part) | BI 894416 54 mg (SRD Part) | BI 894416 70 mg (SRD Part) | BI 894416 10mg tb / 10mg PfOS / 40mg tb | BI 894416 10mg PfOS / 10mg tb / 40mg tb | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Male | 14 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 68 |
| Ethnicity (NIH/OMB)(Participants) | Placebo Matching BI 894416 (SRD Part) | BI 894416 3 Milligram (mg) (SRD Part) | BI 894416 10 mg (SRD Part) | BI 894416 20 mg (SRD Part) | BI 894416 30 mg (SRD Part) | BI 894416 40 mg (SRD Part) | BI 894416 54 mg (SRD Part) | BI 894416 70 mg (SRD Part) | BI 894416 10mg tb / 10mg PfOS / 40mg tb | BI 894416 10mg PfOS / 10mg tb / 40mg tb | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Not Hispanic or Latino | 13 | 6 | 5 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 66 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo Matching BI 894416 (SRD Part) | BI 894416 3 Milligram (mg) (SRD Part) | BI 894416 10 mg (SRD Part) | BI 894416 20 mg (SRD Part) | BI 894416 30 mg (SRD Part) | BI 894416 40 mg (SRD Part) | BI 894416 54 mg (SRD Part) | BI 894416 70 mg (SRD Part) | BI 894416 10mg tb / 10mg PfOS / 40mg tb | BI 894416 10mg PfOS / 10mg tb / 40mg tb | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| White | 14 | 6 | 6 | 6 | 5 | 6 | 6 | 6 | 6 | 6 | 67 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency
Ran from Nov 2017 to primary completion in Sep 2018, 10 months.
Results were first posted in Mar 2024, 5 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BI 894416